1,284.30
+4.9(+0.38%)
Currency In INR
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
27048
First IPO Date
January 01, 1996
| Name | Title | Pay | Year Born |
| Mr. Deepak Sapra M.B.A. | Chief Executive Officer of API & Services & Member of Management Council | 0 | 1975 |
| Mr. Patrick Aghanian B.A., M.B.A. | Chief Executive Officer of European Generics & Member of Management Council | 0 | 1965 |
| Mr. Venkata Ramana Motupalli M.B.A. | Chief Executive Officer of Branded Markets - India & Emerging Countries and Member of Management Council | 0 | 1969 |
| Mr. Erez Israeli M.B.A. | Chief Executive Officer & Member of the Management Council | 0 | 1968 |
| Mr. Kallam Satish Reddy B.Tech., M.S. | Chairman of the Board & Member of the Management Council | 116.17M | 1967 |
| Mr. Gunupati Venkateswara Prasad B.E. | Co-Chairman, MD & Member of Management Council | 186.28M | 1960 |
| Mr. Sanjay Sharma B.Tech. | Executive Vice President, Global Head of Global Manufacturing & Member of Management Council | 0 | 1968 |
| Ms. Archana Bhaskar B.Sc., M.B.A. | EVice President, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council | 0 | 1967 |
| Mr. Krishna K. Venkatesh B.Pharma M.S. | Global Head of Quality and Pharmacovigilance & Member of the Management Council | 0 | 1973 |
| Mr. Mannam Venkatanarasimham | Chief Financial Officer & Member of the Management Council | 0 | N/A |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.